Candriam S.C.A. Has $62.47 Million Stake in BioNTech SE Sponsored ADR $BNTX

Candriam S.C.A. reduced its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 12.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 586,736 shares of the company’s stock after selling 84,219 shares during the period. Candriam S.C.A.’s holdings in BioNTech were worth $62,472,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Banque Cantonale Vaudoise bought a new stake in BioNTech in the 1st quarter valued at about $36,000. LRI Investments LLC grew its stake in BioNTech by 234.6% in the second quarter. LRI Investments LLC now owns 445 shares of the company’s stock valued at $47,000 after acquiring an additional 312 shares during the period. Hantz Financial Services Inc. increased its holdings in shares of BioNTech by 472.0% during the second quarter. Hantz Financial Services Inc. now owns 572 shares of the company’s stock valued at $61,000 after acquiring an additional 472 shares in the last quarter. Banque Transatlantique SA bought a new position in shares of BioNTech in the 1st quarter worth $80,000. Finally, Costello Asset Management INC bought a new position in shares of BioNTech in the 1st quarter worth $91,000. Institutional investors own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Jefferies Financial Group reiterated a “buy” rating on shares of BioNTech in a report on Wednesday. JPMorgan Chase & Co. lowered their target price on shares of BioNTech from $121.00 to $120.00 and set a “neutral” rating on the stock in a report on Thursday, October 23rd. UBS Group lifted their price target on BioNTech from $115.00 to $117.00 and gave the company a “neutral” rating in a research note on Thursday, November 6th. Morgan Stanley reissued an “overweight” rating and issued a $134.00 price objective on shares of BioNTech in a research note on Monday, November 3rd. Finally, Wells Fargo & Company set a $150.00 target price on BioNTech and gave the company an “overweight” rating in a research report on Tuesday, August 5th. Eleven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $134.10.

BioNTech Stock Performance

Shares of BNTX stock opened at $111.61 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.48 and a current ratio of 8.61. The firm has a market cap of $26.84 billion, a price-to-earnings ratio of -69.76 and a beta of 1.54. BioNTech SE Sponsored ADR has a 52 week low of $81.20 and a 52 week high of $129.27. The firm’s 50-day simple moving average is $103.09 and its two-hundred day simple moving average is $104.95.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.89). The firm had revenue of $1.78 billion for the quarter, compared to analysts’ expectations of $1.21 billion. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The firm’s quarterly revenue was up 22.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.81 EPS. BioNTech has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.